Sentences with phrase «novel immune therapies»

Novel immune therapies for prostate and pancreatic cancers, among others, are also in clinical study.

Not exact matches

«It is anticipated that this novel compound will have significant efficacy in human melanomas and other cancers either as a stand - alone therapy or in combination with other targeted or immune - based therapies,» explained co-corresponding author Rhoda Alani, MD, the Herbert Mescon Chair of Dermatology at Boston University School of Medicine (BUSM).

Researchers at The University of Texas MD Anderson Cancer Center developed a novel chimeric mouse model to test the combination therapy using immune checkpoint blockades with therapies targeting myeloid - derived suppressor cells (MDSCs).

He hopes that further studies may identify novel approaches to immune - based cancer therapy or reveal new drug targets for inflammatory diseases.

In a letter to the New England Journal of Medicine, a Massachusetts General Hospital (MGH) research team reports a remarkable treatment response in a patient participating in a clinical trial of a novel immune - system - based cancer therapy.

The novel drug combination allows the rapidly emerging cancer therapies called immune checkpoint inhibitors to be incorporated into a transplant patient's cancer treatment regimen.

As demonstrated by the breadth of clinical trial involvement shown above, CCIR members are testing the utility of immune checkpoint blockade in lymphoma (shown by Dr. Allison to be effective against melanoma), genetic engineering in cell therapy (e.g., CD19, CXCR2, TGF - β DNR), and TLR agonists or IL - 2 in vaccine formulations as well as some novel combination therapies, such as the infusion of tumor - reactive lymphocytes from HLA - matched donors who were vaccinated with a lymphoma idiotype.

For their collective contributions to the pre-clinical foundation and development of immune checkpoint blockade, a novel form of cancer therapy that has transformed the landscape of cancer treatment.

Founded in 2014, ImmunXperts provides immunogenicity and immune - oncology screening services, assessing all aspects of the immune responses in donors and patients, supporting its partners in the full development cycle of novel drugs, biotherapeutics and stem cell therapies.

In the last decade, Foxp3 + Treg cells have raised the hope for novel cell - based therapies to achieve tolerance in clinical settings of unwanted immune responses such as autoimmunity and graft rejection.

Through understanding the biology of cancer cells and their interaction with the immune system we are able to discover and trial novel therapies to induce the immune system to detect and fight cancer cells.

GigaGen is a biopharmaceutical company that develops novel antibody therapies derived from immune repertoires.

GigaGen's proprietary approach delivers unprecedented insights into immune regulatory pathways and what causes them to fail, enabling a pipeline of novel antibody therapies for patients with cancer and immune deficiency diseases.

These combined clinical and laboratory resources accelerate the development of novel therapeutics, including immune therapies — resulting in optimized, personalized cancer treatments.

This novel approach, which reveals complex interactions between cells and proteins, can also be used for other diseases to generate new knowledge about the regulation and dysregulation of the immune system, which can eventually give rise to new, improved immunological therapies.

The results of her project will help scientists develop novel therapies to target the regulatory proteins that cause CD47 overproduction in leukemia and other cancer stem cells, with the goal of restoring immunosurveillance and enabling the immune system to recognize and destroy these aberrant cancer cells.

In honor of James Allison, Lieping Chen, Gordon Freeman, Tasuku Honjo and Arlene Sharpe for contributions to the pre-clinical foundation and development of immune checkpoint blockade, a novel form of cancer therapy that has transformed the landscape of cancer treatment.

Led by Christiana Davis, MD, (in collaboration with Dr. Peter Gabriel, Chief Oncology Informatics Officer and Abigail Doucette, MPH, Research Registry Program Manager), the Thoracic TCE has established project - based databases to track the demographics and response status of patients to immune - oncology treatments, as well as acquired resistance to standard therapies and novel targeted immunotherapies.

The approach is to use clinically relevant tumor models such as patient - derived xenografts (PDXs), as well as humanized and immunocompetent transgenic tumor - bearing mice to design rational combinations of novel and emerging cancer therapies, including tumor - targeting and immune - stimulating therapies, to ultimately improve treatment outcomes for cancer patients.

Munich, Germany About Blog Definiens mission is to accelerate breakthroughs for this approach by helping scientists leverage Tissue Phenomics to deepen understanding of disease biology and immune system mechanisms, to bring multi-omics data into a cancer - relevant context, and to facilitate the translation of new insights into novel therapies and treatment strategies.

Melanoma seems to be uniquely responsive to immune - based therapies, and various novel approaches are under development to treat this disease.

Research Interests Critical care of polytrauma patients, troponin as a biomarker in traumatic myocarditis, the application of Continuous Renal Replacement Therapy (dialysis) for companion animals with acute kidney failure, advanced therapeutic approaches to immune mediated hemolytic anemia, and novel laboratory assessment of coagulopathies (including thromboelastography and platelet aggregometry).

Munich, Germany About Blog Definiens mission is to accelerate breakthroughs for this approach by helping scientists leverage Tissue Phenomics to deepen understanding of disease biology and immune system mechanisms, to bring multi-omics data into a cancer - relevant context, and to facilitate the translation of new insights into novel therapies and treatment strategies.

Munich, Germany About Blog Definiens mission is to accelerate breakthroughs for this approach by helping scientists leverage Tissue Phenomics to deepen understanding of disease biology and immune system mechanisms, to bring multi-omics data into a cancer - relevant context, and to facilitate the translation of new insights into novel therapies and treatment strategies.

Munich, Germany About Blog Definiens mission is to accelerate breakthroughs for this approach by helping scientists leverage Tissue Phenomics to deepen understanding of disease biology and immune system mechanisms, to bring multi-omics data into a cancer - relevant context, and to facilitate the translation of new insights into novel therapies and treatment strategies.

Munich, Germany About Blog Definiens mission is to accelerate breakthroughs for this approach by helping scientists leverage Tissue Phenomics to deepen understanding of disease biology and immune system mechanisms, to bring multi-omics data into a cancer - relevant context, and to facilitate the translation of new insights into novel therapies and treatment strategies.